The firmest GLP-1 mental health evidence sits in depression and alcohol use

Depression scores dropped significantly in people taking a GLP-1 medicine compared with people taking a placebo, in one study. A separate trial ran 30 weeks in patients with schizophrenia, prediabetes and obesity, lowered blood glucose and weight by an average of 20.3 pounds, and improved physical quality of life without mental health getting worse.

Biology gives the idea a spine. GLP-1 is a hormone the intestinal tract releases when food arrives and the brain makes on its own, and it slows stomach emptying, signals fullness, and reaches the reward circuitry that handles appetite and drug intake while damping inflammation. Evidence for alcohol and other substance use disorders rests on that same reward pathway, where these medicines quiet dopamine release.

Where the effect showed up is the limit. One trial found a GLP-1 drug cut heavy drinking days and total alcohol intake only in a subset of participants with obesity, and across the literature overweight, obese and diabetic subjects respond better than normal-weight ones, a narrower claim than a psychiatric treatment. What is still unknown is how much of this survives outside those groups, and any of it belongs with a qualified clinician who knows a person's health history.

Read the full story at Psychology Today ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.